Sintilimab
Sintilimab, sold under the brand Tyvyt among others, is a medication used to treat Hodgkin's disease,[2] and has been approved in China.[3]
Monoclonal antibody | |
---|---|
Type | ? |
Clinical data | |
Other names | Anti-PDCD1 monoclonal antibody IBI308[1] |
Identifiers | |
CAS Number | |
UNII |
It is a fully human IgG4 monoclonal antibody[4] that binds to programmed cell death protein 1.[5]
It was jointly developed by Innovent Biologics[6] and Eli Lilly.[7]
Medical uses
Sintilimab is medication that is indicated for the treatment of relapsed or refractory classical Hodgkin's lymphoma[8] after failure of at least second-line systemic chemotherapy.[5]
Side effects
Common side effects include fever, thyroid dysfunction, elevation of liver enzymes, and lung inflammation.[9]
Research
Currently, more than 20 clinical trials are ongoing to evaluate the anti-tumor effect of sintilimab injection, either as monotherapy or in combination with other agents, on a variety of solid tumors[10]. On January 2019, the result of the registration trial of sintilimab in people with refractory or relapsed classical Hodgkin's lymphoma was published.[8]
References
- "anti-PDCD1 monoclonal antibody IBI308 - National Cancer Institute". National Cancer Institute.
- "Antibody Drug Conjugates Market Growth Forecast Analysis by Manufacturers, Regions, Type and Application to 2026". Reuters. October 24, 2018.
- "NMPA Approves Tyvyt For Hodgkin's lymphoma Read more from Asian Scientist Magazine". Asian Scientist Magazine. January 9, 2019.
- "OA08 Efficacy and Safety of Sintilimab Combined with 1st Line Chemotherapy in Advanced Squamous Cell Non-small Cell Lung Cancer". Journal of Thoracic Oncology. Retrieved Dec 1, 2018.
- SM Hoy (11 February 2019). "Sintilimab: First Global Approval. - NCBI". Drugs. 79 (3): 341–346. doi:10.1007/s40265-019-1066-z. PMID 30742278.
- "Chi-Med Announces Amendment to the 2013 License & Collaboration Agreement on Fruquintinib with Eli Lilly and Company". SEC.gov. December 20, 2018.
- "Sintilimab - Eli Lilly/Innovent Biologics - AdisInsight - Springer". Springer. 28 Mar 2019.
- Stephen M. Ansell (Jan 1, 2019). "Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma". The Lancet.
- "A first-in-human phase 1a trial of sintilimab (IBI308)". American Society of Clinical Oncology. 12 October 2019.
- "Innovent Organized a Forum Discussing the Pending Launch of its Anti PD-1 Tyvyt® (Sintilimab injection)". The New York Times. Retrieved Feb 22, 2019.